
ENTX Stock Forecast & Price Target
ENTX Analyst Ratings
Bulls say
Entera Bio is well-positioned for success with its promising product pipeline and strategic plans for advancing their oral treatment options for underserved medical conditions. With next-generation EB613 slated to enter late-phase trials in 2026 and a strong leadership team, the company is on track to meet its goal of FDA approval in 2029. Furthermore, the recent equity financing has extended the company's runway, providing them with the necessary resources to move forward with their pivotal program and potentially reach commercialization.
Bears say
Entera Bio is currently facing a significant hurdle in obtaining FDA approval for its lead product candidate, EB613, as the company has yet to receive feedback from the FDA on its Phase 3 protocol and statistical analysis plan. Given the company's reliance on the combination of its oral peptide platform and a well-established drug for its indication, a favorable response from the FDA is crucial for the company's success. It is also worth noting that the company has no current product revenue and any further delays in obtaining FDA approval could potentially harm its financials.
This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ENTX Analyst Forecast & Price Prediction
Start investing in ENTX
Order type
Buy in
Order amount
Est. shares
0 shares